Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia
2013
Yoshida, Hiroshi | Shoda, Toru | Yanai, Hidekatsu | Ikewaki, Katsunori | Kurata, Hideaki | Ito, Kumie | Furutani, Nobuyuki | Tada, Norio | Witztum, Joseph L. | Tsimikas, Sotirios
OBJECTIVE: The effects of potent statins on oxidized lipoprotein biomarkers are not well defined. METHODS AND RESULTS: The VISION (Value of oxIdant lipid lowering effect by Statin InterventiON in hypercholesterolemia) Trial randomized patients with hypercholesterolemia to 12-week administration of pitavastatin 2 mg/day (n = 21) or atorvastatin 10 mg/day (n = 21) and a variety of lipoprotein oxidative biomarkers were measured. Between-group analysis did not reveal any differences except in the ratio of malondialdehyde (MDA)-LDL over apolipoprotein B-100 (MDA-LDL/apoB) in pitavastatin vs. atorvastatin group (−13% vs. −0.7%, p = 0.04). Within-group changes from baseline to 12-week revealed significant increases in OxPL/apoB and reductions in small-dense LDL, MDA-LDL, and lipoprotein-associated phospholipase A₂ measured on circulating apoB particles (Lp-PLA₂/apoB) in both groups and significant reductions in OxPL/apoAI in the atorvastatin group. CONCLUSIONS: The VISION study describes the first comparison on lipoprotein oxidation biomarkers between pitavastatin and atorvastatin and suggests diverse effects on lipoprotein oxidation markers in patients with hypercholesterolemia.
显示更多 [+] 显示较少 [-]